|
Project Name
|
Synthetic HDL-mimicking nanoparticle（MaRS）
|
|
Project Information
|
Company Introduction
DLVR Therapeutics Inc. is a privately held biotechnology company co-founded in 2011 by University Health Network, the Ontario Institute for Cancer Research and MaRS Innovation. The company is developing a novel nanoparticle delivery system based on a high-density lipoprotein (HDL)-mimicking Peptide-Phospholipid Scaffold (HPPS) that is suitable for a variety of different payloads. DLVR’s initial focus is on siRNA for oncological indications where there is a tremendous unmet need.
The company’s two principal programs are: 1) Targeted delivery of siRNA. Therapeutic application of RNA interference (RNAi) requires delivery of siRNAs into the cytoplasm of targeted cells. DLVR’s HPPS technology directs siRNA to the cytoplasm, unlike the majority of competing approaches to siRNA delivery. With proof-of-concept studies completed demonstrating effective in vivo delivery of siRNA, DLVR is securing target-based collaborations with pharmaceutical companies for siRNA delivery partnerships. 2) Improving the therapeutic index of known chemotherapeutic drugs; DLVR is currently exploring several different chemotherapeutic compounds with the potential to meet this profile.
DLVR has raised million in seed funding and will be seeking million in the next six to eight months to support clinical development of its HPPS delivery platform for siRNA and chemotherapeutic delivery.
|
|
The current development situation and progress
• Completed proof-of-concept studies demonstrating HPPS-siRNA in vivo target knockdown and tumor inhibition.
• Entered into its first relationship with a biopharmaceutical partner in the area of siRNA delivery with HPPS.
• Completed proof-of-concept studies demonstrating HPPS-paclitaxel oleate targeting to SR-B1-overexpressing tumors.
|
The project will be expired in three months, for more project information, please contact: services@beijing-ontario.org